Compare CMCO & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CMCO | KROS |
|---|---|---|
| Founded | 1875 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Construction/Ag Equipment/Trucks | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 600.1M | 584.9M |
| IPO Year | 1996 | 2020 |
| Metric | CMCO | KROS |
|---|---|---|
| Price | $21.62 | $17.89 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 9 |
| Target Price | ★ $35.00 | $23.00 |
| AVG Volume (30 Days) | ★ 412.5K | 329.3K |
| Earning Date | 02-09-2026 | 02-25-2026 |
| Dividend Yield | ★ 1.33% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | 0.13 | ★ 1.57 |
| Revenue | ★ $977,994,000.00 | $246,718,000.00 |
| Revenue This Year | $5.60 | $6,924.79 |
| Revenue Next Year | $4.23 | N/A |
| P/E Ratio | $160.57 | ★ $11.73 |
| Revenue Growth | N/A | ★ 37798.31 |
| 52 Week Low | $11.78 | $9.12 |
| 52 Week High | $35.80 | $22.55 |
| Indicator | CMCO | KROS |
|---|---|---|
| Relative Strength Index (RSI) | 67.49 | 41.95 |
| Support Level | $20.59 | $17.65 |
| Resistance Level | $21.43 | $18.74 |
| Average True Range (ATR) | 0.77 | 0.65 |
| MACD | -0.05 | -0.07 |
| Stochastic Oscillator | 67.48 | 13.76 |
Columbus McKinnon Corp is a designer, manufacturer, and marketer of intelligent motion solutions, including motion control products, technologies, automated systems, and services that efficiently and ergonomically move, lift, position, and secure materials. Its key products include hoists, crane components, precision conveyors, actuators, rigging tools, light rail workstations, and digital power and motion control systems. The company's targeted market verticals include general industries, process industries, industrial automation, and e-commerce/supply chain/warehousing among others. Geographically, the company generates a majority of its revenue from the United States and the rest from Germany, Canada, Asia Pacific, Latin America, Europe, the Middle East, and Africa.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.